Collectively, these studies in human samples, GEM models, and cancer cell lines demonstrate that histone methyltransferase ASH1L is genetically amplified and overexpressed in metastatic PCa, among other malignancies. This evidence concerns the gene PRDM9 and posterior cortical atrophy.